Drug resistance restrains the efficacy of platinum-based chemotherapy against esophageal squamous cell carcinoma (ESCC). Long noncoding RNAs (lncRNAs) play crucial roles in various cancers. In this study, we conducted bioinformatical analysis to search for key lncRNAs involved in ESCC progression. Experimental validations focused on a candidate lncRNA, HMGA2-AS1. The roles of the lncRNA HMGA2-AS1 in ESCC growth and cisplatin resistance were explored. The clinical significance of HMGA2-AS1 in ESCC was also determined. Our data demonstrated that HMGA2-AS1 was significantly upregulated in ESCC relative to adjacent normal tissues and correlated with tumor size (p = 0.0035) and tumor stage (p = 0.0001). Knockdown of HMGA2-AS1 suppressed the proliferation and colony formation and increased cisplatin sensitivity in ESCC cells. In vivo tumorigenic studies showed that depletion of HMGA2-AS1 impaired tumorigenesis of ESCC cells. Enforced expression of HMGA2-AS1 promoted ESCC proliferation and cisplatin resistance. HMGA2-AS1 interacted with HMGA2 protein in the nucleus of ESCC cells, promoting HMGA2-dependent transactivation of Snail2. Silencing of HMGA2 abrogated HMGA2-AS1-induced proliferation and cisplatin resistance in ESCC cells, which were rescued by overexpression of Snail2. In conclusion, our results highlight the importance of HMGA2-AS1 in ESCC growth and cisplatin resistance. HMGA2-AS1-induced aggressive phenotype in ESCC depends on the interaction with HMGA2. HMGA2-AS1 may serve as a potential therapeutic target for ESCC.
MorganESoerjomataramIRumgayH, et al. The global landscape of esophageal squamous cell carcinoma and esophageal adenocarcinoma incidence and mortality in 2020 and projections to 2040: new estimates from GLOBOCAN 2020. Gastroenterology2022; 163: 649–658.
2.
ArnoldMFerlayJvan Berge HenegouwenMI, et al. Global burden of oesophageal and gastric cancer by histology and subsite in 2018. Gut2020; 69: 1564–1571.
3.
LiJChenZBaiY, et al. First-line sugemalimab with chemotherapy for advanced esophageal squamous cell carcinoma: a randomized phase 3 study. Nat Med2024; 30: 740–748.
4.
TasnimSSudarshanM.Staying a step ahead: tailoring chemotherapy for esophageal cancer. Ann Surg Oncol2024; 31: 2200–2201.
5.
LiangYMaedaOMiyataK, et al. Genetic polymorphisms as predictive biomarkers of adverse events during preoperative chemotherapy in esophageal cancer. Cancer Chemother Pharmacol2024; 93: 121–127.
6.
BhattacharjeeRPrabhakarNKumarL, et al. Crosstalk between long noncoding RNA and microRNA in cancer. Cell Oncol2023; 46: 885–908.
7.
JiangYGuoHTongT, et al. LncRNA lnc-POP1-1 upregulated by VN1R5 promotes cisplatin resistance in head and neck squamous cell carcinoma through interaction with MCM5. Mol Ther2022; 30: 448–467.
8.
ChenHWangLLiuJ, et al. LncRNA ITGB2-AS1 promotes cisplatin resistance of non-small cell lung cancer by inhibiting ferroptosis via activating the FOSL2/NAMPT axis. Cancer Biol Ther2023; 24: 2223377.
9.
ChenZWangQHuangL, et al. LncRNA PVT1 confers cisplatin resistance of esophageal cancer cells through modulating the miR-181a-5p-glutaminase (GLS) axis. Nutr Cancer2023; 75: 1646–1657.
10.
BiaynaJDumbovićG.Decoding subcellular RNA localization one molecule at a time. Genome Biol2025; 26: 45.
11.
ZhangZLuYXLiuF, et al. LncRNA BREA2 promotes metastasis by disrupting the WWP2-mediated ubiquitination of Notch1. Proc Natl Acad Sci U S A2023; 120: e2206694120.
12.
GuoRSuYZhangQ, et al. LINC00478-derived novel cytoplasmic lncRNA LacRNA stabilizes PHB2 and suppresses breast cancer metastasis via repressing MYC targets. J Transl Med2023; 21: 120.
13.
StatelloLGuoCJChenLL, et al. Gene regulation by long non-coding RNAs and its biological functions. Nat Rev Mol Cell Biol2021; 22: 96–118.
14.
MattickJSAmaralPPCarninciP, et al. Long non-coding RNAs: definitions, functions, challenges and recommendations. Nat Rev Mol Cell Biol2023; 24: 430–447.
15.
TanYTLinJFLiT, et al. LncRNA-mediated posttranslational modifications and reprogramming of energy metabolism in cancer. Cancer Commun2021; 41: 109–120.
16.
JiangKWuLYinX, et al. Prognostic implications of necroptosis-related long noncoding RNA signatures in muscle-invasive bladder cancer. Front Genet2022; 13: 1036098.
17.
RosGPegoraroSDe AngelisP, et al. HMGA2 antisense long non-coding RNAs as new players in the regulation of HMGA2 expression and pancreatic cancer promotion. Front Oncol2020; 9: 1526.
18.
RothzergEHoXDXuJ, et al. Upregulation of 15 antisense long non-coding RNAs in osteosarcoma. Genes2021; 12: 1132.
19.
YangZLiXZhouL, et al. Ferroptosis-related lncRNAs: distinguishing heterogeneity of the tumour microenvironment and predicting immunotherapy response in bladder cancer. Heliyon2024; 10: e32018.
20.
MiaoHWangLZhanH, et al. A long noncoding RNA distributed in both nucleus and cytoplasm operates in the PYCARD-regulated apoptosis by coordinating the epigenetic and translational regulation. PLoS Genet2019; 15: e1008144.
21.
LiuTHanCFangP, et al. Cancer-associated fibroblast-specific lncRNA LINC01614 enhances glutamine uptake in lung adenocarcinoma. J Hematol Oncol2022; 15: 141.
22.
WuYWangXXuF, et al. The regulation of acetylation and stability of HMGA2 via the HBXIP-activated Akt-PCAF pathway in promotion of esophageal squamous cell carcinoma growth. Nucleic Acids Res2020; 48: 4858–4876.
23.
LiZWuXLiJ, et al. HMGA2-Snai2 axis regulates tumorigenicity and stemness of head and neck squamous cell carcinoma. Exp Cell Res2022; 418: 113271.
24.
DongZBXiangHTWuHM, et al. LncRNA expression signature identified using genome-wide transcriptomic profiling to predict lymph node metastasis in patients with stage T1 and T2 gastric cancer. Gastric Cancer2023; 26: 947–957.
25.
ZhangCZhouYZhangB, et al. Identification of lncRNA, miRNA and mRNA expression profiles and ceRNA networks in small cell lung cancer. BMC Genomics2023; 24: 217.
26.
KhadirnaikarSNarayananSPShuklaSK.Decoding the lncRNA transcriptome of esophageal cancer: identification of clinically relevant lncRNAs. Biomark Med2018; 12: 1083–1093.
27.
SongWZouSB.Prognostic role of lncRNA HOTAIR in esophageal squamous cell carcinoma. Clin Chim Acta2016; 463: 169–173.
28.
FanCGonzález-PrietoRKuipersTB, et al. The lncRNA LETS1 promotes TGF-β-induced EMT and cancer cell migration by transcriptionally activating a TβR1-stabilizing mechanism. Sci Signal2023; 16: eadf1947.
29.
WuGSuJZengL, et al. LncRNA BCAN-AS1 stabilizes c-Myc via N6-methyladenosine-mediated binding with SNIP1 to promote pancreatic cancer. Cell Death Differ2023; 30: 2213–2230.
30.
SuTZhangNWangT, et al. Super enhancer-regulated LncRNA LINC01089 induces alternative splicing of DIAPH3 to drive hepatocellular carcinoma metastasis. Cancer Res2023; 83: 4080–4094.
31.
MaYZhuYShangL, et al. LncRNA XIST regulates breast cancer stem cells by activating proinflammatory IL-6/STAT3 signaling. Oncogene2023; 42: 1419–1437.
32.
MaruyamaTSaitoKHigurashiM, et al. HMGA2 drives the IGFBP1/AKT pathway to counteract the increase in P27KIP1 protein levels in mtDNA/RNA-less cancer cells. Cancer Sci2023; 114: 152–163.
33.
LuoZZhengQYeS, et al. HMGA2 alleviates ferroptosis by promoting GPX4 expression in pancreatic cancer cells. Cell Death Dis2024; 15: 220.
34.
WangJChenYZengZ, et al. HMGA2 contributes to vascular development and sprouting angiogenesis by promoting IGFBP2 production. Exp Cell Res2021; 408: 112831.
35.
LiuBChenGHeQ, et al. An HMGA2-p62-ERα axis regulates uterine leiomyomas proliferation. FASEB J2020; 34: 10966–10983.
36.
MasuoKChenRYogoA, et al. SNAIL2 contributes to tumorigenicity and chemotherapy resistance in pancreatic cancer by regulating IGFBP2. Cancer Sci2021; 112: 4987–4999.
37.
WangFLuoMChengY.KLF5 promotes esophageal squamous cell cancer through the transcriptional activation of FGFBP1. Med Oncol2023; 41: 17.
38.
TaniH.RMST: a long noncoding RNA involved in cancer and disease. J Biochem2025; 177: 73–78.
